Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 2,511 Shares of Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 2,511 shares of the stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total value of $267,321.06. Following the transaction, the chief financial officer owned 41,967 shares of the company’s stock, valued at $4,467,806.82. This represents a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Glaukos Stock Down 4.3%

Shares of NYSE GKOS opened at $103.13 on Friday. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $130.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. The business has a fifty day moving average of $112.94 and a two-hundred day moving average of $101.89. The stock has a market cap of $5.99 billion, a PE ratio of -31.63 and a beta of 0.70.

Glaukos (NYSE:GKOS) last posted its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm’s revenue for the quarter was up 35.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.40) EPS. As a group, equities research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Glaukos

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 198 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Glaukos by 41.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares during the last quarter. Swiss National Bank boosted its stake in Glaukos by 1.0% in the second quarter. Swiss National Bank now owns 108,000 shares of the medical instruments supplier’s stock valued at $11,155,000 after acquiring an additional 1,100 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Glaukos by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 642,437 shares of the medical instruments supplier’s stock worth $66,357,000 after purchasing an additional 59,389 shares during the period. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

GKOS has been the topic of several research analyst reports. UBS Group upped their price objective on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Needham & Company LLC boosted their target price on Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Stifel Nicolaus increased their price target on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Truist Financial lifted their price objective on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.69.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.